Needham initiated coverage of PVH Corp. (PVH) with a Buy rating and $115 price target The firm believes PVH is a “mispriced asset, with underappreciated” earnings drivers over the next few years. In fiscal 2026 and 2027, there will be over $1.00 in earnings per share accretion from taking the G-III licenses in-house, which is not currently reflected in Street estimates, the analyst tells investors in a research note. Additionally, PVH’s cost-efficiency focus has been masked by deleverage on falling sales, but with revenues likely to resume growth this year, the company may see expense leverage in the coming years, contends Needham.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVH:
- PVH Corp. price target raised to $150 from $140 at UBS
- PVH Corp. price target raised to $99 from $87 at JPMorgan
- “30% Rally” For PVH, says Jefferies, PVH Stock (NYSE:PVH) Surges
- UnitedHealth, Wayfair downgraded: Wall Street’s top analyst calls
- PVH Corp. price target raised to $100 from $85 at Wells Fargo
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue